Overview
Vaxxinity is a clinical-stage biotechnology company developing a proprietary platform of synthetic peptide vaccines designed to harness the immune system for treating chronic and infectious diseases. The company's Vaxxine Platform technology stimulates selective immune activation to overcome immune tolerance, converting the body into a natural antibody-producing system. Vaxxinity's pipeline targets neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, as well as cardiovascular conditions such as hypercholesterolemia and infectious diseases including COVID-19, with the overarching mission to democratize global healthcare by making effective immunotherapies accessible and affordable worldwide.